Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study

INTRODUCTION: Empagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves glycaemic control in patients with type 2 diabetes mellitus (T2DM) by inducing urinary glucose excretion. Combination therapy with empagliflozin and glucagon-like peptide-1 (GLP-1) receptor ago...

Descripción completa

Detalles Bibliográficos
Autores principales: Terauchi, Yasuo, Utsunomiya, Kazunori, Yasui, Atsutaka, Seki, Tetsuo, Cheng, Gang, Shiki, Kosuke, Lee, Jisoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531579/
https://www.ncbi.nlm.nih.gov/pubmed/30912033
http://dx.doi.org/10.1007/s13300-019-0604-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531579/
https://www.ncbi.nlm.nih.gov/pubmed/30912033
http://dx.doi.org/10.1007/s13300-019-0604-8

Ejemplares similares